Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease

NCT02370888 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Leukemia, Myeloid
Myelodysplastic Syndromes

Interventions

DRUG: Lenalidomide

Sponsor

University of Florida

Collaborators

[object Object]